shengnuobiotechnologys’ peptide preparations are based on the company’s large-scale production capacity of peptide APIs.

shengnuobiotechnology stated that the company has always focused on improving corporate operating efficiency, continuously improved intrinsic value, and continued to strengthen the R&D pipeline of advantageous products and key technologies in core areas; and based on in-depth understanding of the industry and in-depth exploration of customer needs, through internal Develop in both production and extension to create a full industry chain enterprise for peptide drugs.

Public information shows that shengnuobiotechnology has always focused on the field of peptide medicine since its establishment. Its main business includes: CDMO services for innovative peptide drugs, independently developed and sold peptide APIs and preparations, customized production services for peptide products, and peptide drugs. Production technology transfer services.

shengnuobiotechnology stated that its customized production services for peptide APIs and preparations are mainly based on the company’s pharmaceutical research service customer needs, or in accordance with the quality standards and production process requirements provided by other customers, etc., to customize production for customers for clinical trials and commercial sales stages.

The required innovative drug raw materials and preparation products. At present, the treatment fields of shengnuobiotechnologys’ peptide APIs include anti-AIDS, cardiovascular, rare diseases, diabetes, obstetrics, gastrointestinal tract, immunity and other fields.

In addition,shengnuobiotechnologys’ peptide preparations are based on the company’s large-scale production capacity of peptide APIs. The end customers are domestic medical institutions, and their uses include the treatment of premature fetuses, anti-AIDS, and treatment of varicose bleeding, etc.